<?xml version="1.0"?>
<rss version="2.0">
 <channel>
  <title>StreetInsider.com News Articles</title>
  <link>http://www.streetinsider.com</link>
  <description>Latest StreetInsider.com News Articles</description>
  <language>en-us</language>
  <copyright>Copyright 2026, StreetInsider.com</copyright>
  <managingEditor>rss@streetinsider.com (SI RSS)</managingEditor>
  <webMaster>rss@streetinsider.com (SI RSS)</webMaster>
  <lastBuildDate>Tue, 15 Sep 2026 06:00:00 -0400</lastBuildDate>
  <docs>http://blogs.law.harvard.edu/tech/rss</docs>
  <image>
   <url>http://www.streetinsider.com/images/rss_logo.gif</url>
   <title>StreetInsider.com News Articles</title>
   <link>http://www.streetinsider.com</link>
   <width>143</width>
   <height>28</height>
  </image>
  <skipHours>
   <hour>0</hour>
   <hour>1</hour>
   <hour>2</hour>
   <hour>3</hour>
   <hour>21</hour>
   <hour>22</hour>
   <hour>23</hour>
  </skipHours>
  <skipDays>
   <day>Saturday</day>
   <day>Sunday</day>
  </skipDays>
  <item>
   <title>HEALWELL's DARWEN(TM) AI Outperforms Published Foundation Model Benchmarks and Demonstrates Real-World Patient Impact in New Peer-Reviewed Research</title>
   <link>http://www.streetinsider.com/Press+Releases/HEALWELL%27s+DARWEN%28TM%29+AI+Outperforms+Published+Foundation+Model+Benchmarks+and+Demonstrates+Real-World+Patient+Impact+in+New+Peer-Reviewed+Research/27060427.html</link>
   <description>&lt;ul&gt;&lt;li&gt;&lt;p&gt;New research accepted for presentation at AMIA 2026 demonstrates the performance of HEALWELL's DARWEN&amp;#8482; AI-powered SMARTSuite, including clinical summarization results that outperformed published benchmarks for OpenAI's GPT, DeepSeek and Llama across all three measures used to evaluate clinical summarization accuracy.&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;Separate DARWEN&amp;#8482; AI validation research accepted for oral presentation at AI-MEDX 2026 demonstrated nearly 50% higher treatment-plan accuracy than a leading off-the-shelf general-purpose AI model in blinded clinician review, producing more clinically specific outputs, including drugs and doses.&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;New DARWEN&amp;#8482; AI research in the Canadian Journal of Cardiology demonstrates the impact of SMART Patient ID, identifying more than 4,100 heart failure patients</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/HEALWELL%27s+DARWEN%28TM%29+AI+Outperforms+Published+Foundation+Model+Benchmarks+and+Demonstrates+Real-World+Patient+Impact+in+New+Peer-Reviewed+Research/27060427.html</guid>
   <pubDate>Tue, 15 Sep 2026 06:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">AIDX</category>
   	  </item>
  <item>
   <title>HEALWELL's DARWEN(TM) AI Outperforms Published Foundation Model Benchmarks and Demonstrates Real-World Patient Impact in New Peer-Reviewed Research</title>
   <link>http://www.streetinsider.com/Newsfile/HEALWELL%27s+DARWEN%28TM%29+AI+Outperforms+Published+Foundation+Model+Benchmarks+and+Demonstrates+Real-World+Patient+Impact+in+New+Peer-Reviewed+Research/27060427.html</link>
   <description>&lt;ul&gt;&lt;li&gt;&lt;p&gt;New research accepted for presentation at AMIA 2026 demonstrates the performance of HEALWELL's DARWEN&amp;#8482; AI-powered SMARTSuite, including clinical summarization results that outperformed published benchmarks for OpenAI's GPT, DeepSeek and Llama across all three measures used to evaluate clinical summarization accuracy.&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;Separate DARWEN&amp;#8482; AI validation research accepted for oral presentation at AI-MEDX 2026 demonstrated nearly 50% higher treatment-plan accuracy than a leading off-the-shelf general-purpose AI model in blinded clinician review, producing more clinically specific outputs, including drugs and doses.&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;New DARWEN&amp;#8482; AI research in the Canadian Journal of Cardiology demonstrates the impact of SMART Patient ID, identifying more than 4,100 heart failure patients</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Newsfile/HEALWELL%27s+DARWEN%28TM%29+AI+Outperforms+Published+Foundation+Model+Benchmarks+and+Demonstrates+Real-World+Patient+Impact+in+New+Peer-Reviewed+Research/27060427.html</guid>
   <pubDate>Tue, 15 Sep 2026 06:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">AIDX</category>
   	  </item>
  <item>
   <title>Form  8-K        20/20 Biolabs, Inc.       For: Sep 03</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++2020+Biolabs%2C+Inc.+++++++For%3A+Sep+03/27048510.html</link>
   <description>si-local-file:///var/storage/secattach/20260910/27048510.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++2020+Biolabs%2C+Inc.+++++++For%3A+Sep+03/27048510.html</guid>
   <pubDate>Thu, 10 Sep 2026 16:11:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">AIDX</category>
   	  </item>
  <item>
   <title>Healwell's Darwen AI to match clinical trials to 100K+ consented patients</title>
   <link>http://www.streetinsider.com/Corporate+News/Healwell%27s+Darwen+AI+to+match+clinical+trials+to+100K%2B+consented+patients/27032829.html</link>
   <description>&lt;p&gt;Healwell AI Inc. (TSX: AIDX) (OTCQX: HWAIF) and Well Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) announced that their shared patient consent database, WellTrust, has surpassed 100,000 patient consents since its launch in February 2026.&lt;/p&gt;&lt;p&gt;WellTrust is a database of Well Health patients who have expressly agreed to be contacted about clinical trials and research studies matched to their health circumstances. According to the companies, the 100,000 milestone was reached through in-clinic enrollment alone, before the activation of additional digital consent channels.&lt;/p&gt;&lt;p&gt;Healwell's Darwen AI platform will be used to match trial protocols against the consented patient population, connecting patients with pharmaceutical</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Corporate+News/Healwell%27s+Darwen+AI+to+match+clinical+trials+to+100K%2B+consented+patients/27032829.html</guid>
   <pubDate>Tue, 08 Sep 2026 06:34:16 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">AIDX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">WELL</category>
   	  </item>
  <item>
   <title>Healwell's Darwen AI to match clinical trials to 100K+ consented patients</title>
   <link>http://www.streetinsider.com/Corporate+News/Healwell%27s+Darwen+AI+to+match+clinical+trials+to+100K%2B+consented+patients/27032829.html</link>
   <description>&lt;p&gt;Healwell AI Inc. (TSX: AIDX) (OTCQX: HWAIF) and Well Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) announced that their shared patient consent database, WellTrust, has surpassed 100,000 patient consents since its launch in February 2026.&lt;/p&gt;&lt;p&gt;WellTrust is a database of Well Health patients who have expressly agreed to be contacted about clinical trials and research studies matched to their health circumstances. According to the companies, the 100,000 milestone was reached through in-clinic enrollment alone, before the activation of additional digital consent channels.&lt;/p&gt;&lt;p&gt;Healwell's Darwen AI platform will be used to match trial protocols against the consented patient population, connecting patients with pharmaceutical</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Corporate+News/Healwell%27s+Darwen+AI+to+match+clinical+trials+to+100K%2B+consented+patients/27032829.html</guid>
   <pubDate>Tue, 08 Sep 2026 06:34:16 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">AIDX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">WELL</category>
   	  </item>
  <item>
   <title>WELL Health Announces WELLTRUST(TM) Surpasses 100,000 Patient Consents</title>
   <link>http://www.streetinsider.com/Press+Releases/WELL+Health+Announces+WELLTRUST%28TM%29+Surpasses+100%2C000+Patient+Consents/27032821.html</link>
   <description>&lt;ul&gt;&lt;li&gt;WELLTRUST&amp;#8482;, a WELL-managed database of consented WELL patients, has surpassed 100,000 patient consents since launching in February 2026. Every consent represents a patient who has expressly agreed to be contacted about clinical trials and research studies matched to their health circumstances. &lt;/li&gt;&lt;li&gt;HEALWELL's DARWEN&amp;#8482; AI platform is used to connect WELLTRUST&amp;#8482; patients with life sciences companies, including pharma and biotech trial sponsors and Contract Research Organizations (CROs), by matching trial protocols against the consented patient population. &lt;/li&gt;&lt;li&gt;Patient consents are captured and managed using OceanMD, WELLSTAR's patient engagement platform, which presents the WELLTRUST&amp;#8482; consent within the digital check-in workflow patients already use</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/WELL+Health+Announces+WELLTRUST%28TM%29+Surpasses+100%2C000+Patient+Consents/27032821.html</guid>
   <pubDate>Tue, 08 Sep 2026 06:30:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">AIDX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">WELL</category>
   	  </item>
  <item>
   <title>WELL Health Announces WELLTRUST(TM) Surpasses 100,000 Patient Consents</title>
   <link>http://www.streetinsider.com/Press+Releases/WELL+Health+Announces+WELLTRUST%28TM%29+Surpasses+100%2C000+Patient+Consents/27032821.html</link>
   <description>&lt;ul&gt;&lt;li&gt;WELLTRUST&amp;#8482;, a WELL-managed database of consented WELL patients, has surpassed 100,000 patient consents since launching in February 2026. Every consent represents a patient who has expressly agreed to be contacted about clinical trials and research studies matched to their health circumstances. &lt;/li&gt;&lt;li&gt;HEALWELL's DARWEN&amp;#8482; AI platform is used to connect WELLTRUST&amp;#8482; patients with life sciences companies, including pharma and biotech trial sponsors and Contract Research Organizations (CROs), by matching trial protocols against the consented patient population. &lt;/li&gt;&lt;li&gt;Patient consents are captured and managed using OceanMD, WELLSTAR's patient engagement platform, which presents the WELLTRUST&amp;#8482; consent within the digital check-in workflow patients already use</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/WELL+Health+Announces+WELLTRUST%28TM%29+Surpasses+100%2C000+Patient+Consents/27032821.html</guid>
   <pubDate>Tue, 08 Sep 2026 06:30:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">AIDX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">WELL</category>
   	  </item>
  <item>
   <title>WELL Health Announces WELLTRUST(TM) Surpasses 100,000 Patient Consents</title>
   <link>http://www.streetinsider.com/Newsfile/WELL+Health+Announces+WELLTRUST%28TM%29+Surpasses+100%2C000+Patient+Consents/27032821.html</link>
   <description>&lt;ul&gt;&lt;li&gt;WELLTRUST&amp;#8482;, a WELL-managed database of consented WELL patients, has surpassed 100,000 patient consents since launching in February 2026. Every consent represents a patient who has expressly agreed to be contacted about clinical trials and research studies matched to their health circumstances. &lt;/li&gt;&lt;li&gt;HEALWELL's DARWEN&amp;#8482; AI platform is used to connect WELLTRUST&amp;#8482; patients with life sciences companies, including pharma and biotech trial sponsors and Contract Research Organizations (CROs), by matching trial protocols against the consented patient population. &lt;/li&gt;&lt;li&gt;Patient consents are captured and managed using OceanMD, WELLSTAR's patient engagement platform, which presents the WELLTRUST&amp;#8482; consent within the digital check-in workflow patients already use</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Newsfile/WELL+Health+Announces+WELLTRUST%28TM%29+Surpasses+100%2C000+Patient+Consents/27032821.html</guid>
   <pubDate>Tue, 08 Sep 2026 06:30:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">AIDX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">WELL</category>
   	  </item>
  <item>
   <title>WELL Health Announces WELLTRUST(TM) Surpasses 100,000 Patient Consents</title>
   <link>http://www.streetinsider.com/Newsfile/WELL+Health+Announces+WELLTRUST%28TM%29+Surpasses+100%2C000+Patient+Consents/27032821.html</link>
   <description>&lt;ul&gt;&lt;li&gt;WELLTRUST&amp;#8482;, a WELL-managed database of consented WELL patients, has surpassed 100,000 patient consents since launching in February 2026. Every consent represents a patient who has expressly agreed to be contacted about clinical trials and research studies matched to their health circumstances. &lt;/li&gt;&lt;li&gt;HEALWELL's DARWEN&amp;#8482; AI platform is used to connect WELLTRUST&amp;#8482; patients with life sciences companies, including pharma and biotech trial sponsors and Contract Research Organizations (CROs), by matching trial protocols against the consented patient population. &lt;/li&gt;&lt;li&gt;Patient consents are captured and managed using OceanMD, WELLSTAR's patient engagement platform, which presents the WELLTRUST&amp;#8482; consent within the digital check-in workflow patients already use</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Newsfile/WELL+Health+Announces+WELLTRUST%28TM%29+Surpasses+100%2C000+Patient+Consents/27032821.html</guid>
   <pubDate>Tue, 08 Sep 2026 06:30:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">AIDX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">WELL</category>
   	  </item>
  <item>
   <title>HEALWELL's DARWEN(TM) to Power AI-Driven Clinical Trial Matching for WELLTRUST(TM), a Network of Over 100,000 Consented Patients</title>
   <link>http://www.streetinsider.com/Press+Releases/HEALWELL%27s+DARWEN%28TM%29+to+Power+AI-Driven+Clinical+Trial+Matching+for+WELLTRUST%28TM%29%2C+a+Network+of+Over+100%2C000+Consented+Patients/27032822.html</link>
   <description>&lt;ul&gt;&lt;li&gt;HEALWELL's DARWEN&amp;#8482; AI platform is used to connect WELLTRUST&amp;#8482; patients with life sciences companies, including pharma and biotech trial sponsors and Contract Research Organizations (CROs), by matching trial protocols against the consented patient population. &lt;/li&gt;&lt;li&gt;WELLTRUST&amp;#8482;, a WELL-managed database of consented WELL patients, has surpassed 100,000 patient consents since launching in February 2026. Every consent represents a patient who has expressly agreed to be contacted about clinical trials and research studies matched to their health circumstances. &lt;/li&gt;&lt;li&gt;Patient consents are captured and managed using OceanMD, WELLSTAR's patient engagement platform, which presents the WELLTRUST&amp;#8482; consent within the digital check-in workflow patients already use</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/HEALWELL%27s+DARWEN%28TM%29+to+Power+AI-Driven+Clinical+Trial+Matching+for+WELLTRUST%28TM%29%2C+a+Network+of+Over+100%2C000+Consented+Patients/27032822.html</guid>
   <pubDate>Tue, 08 Sep 2026 06:30:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">AIDX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">WELL</category>
   	  </item>
  <item>
   <title>HEALWELL's DARWEN(TM) to Power AI-Driven Clinical Trial Matching for WELLTRUST(TM), a Network of Over 100,000 Consented Patients</title>
   <link>http://www.streetinsider.com/Press+Releases/HEALWELL%27s+DARWEN%28TM%29+to+Power+AI-Driven+Clinical+Trial+Matching+for+WELLTRUST%28TM%29%2C+a+Network+of+Over+100%2C000+Consented+Patients/27032822.html</link>
   <description>&lt;ul&gt;&lt;li&gt;HEALWELL's DARWEN&amp;#8482; AI platform is used to connect WELLTRUST&amp;#8482; patients with life sciences companies, including pharma and biotech trial sponsors and Contract Research Organizations (CROs), by matching trial protocols against the consented patient population. &lt;/li&gt;&lt;li&gt;WELLTRUST&amp;#8482;, a WELL-managed database of consented WELL patients, has surpassed 100,000 patient consents since launching in February 2026. Every consent represents a patient who has expressly agreed to be contacted about clinical trials and research studies matched to their health circumstances. &lt;/li&gt;&lt;li&gt;Patient consents are captured and managed using OceanMD, WELLSTAR's patient engagement platform, which presents the WELLTRUST&amp;#8482; consent within the digital check-in workflow patients already use</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/HEALWELL%27s+DARWEN%28TM%29+to+Power+AI-Driven+Clinical+Trial+Matching+for+WELLTRUST%28TM%29%2C+a+Network+of+Over+100%2C000+Consented+Patients/27032822.html</guid>
   <pubDate>Tue, 08 Sep 2026 06:30:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">AIDX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">WELL</category>
   	  </item>
  <item>
   <title>HEALWELL's DARWEN(TM) to Power AI-Driven Clinical Trial Matching for WELLTRUST(TM), a Network of Over 100,000 Consented Patients</title>
   <link>http://www.streetinsider.com/Newsfile/HEALWELL%27s+DARWEN%28TM%29+to+Power+AI-Driven+Clinical+Trial+Matching+for+WELLTRUST%28TM%29%2C+a+Network+of+Over+100%2C000+Consented+Patients/27032822.html</link>
   <description>&lt;ul&gt;&lt;li&gt;HEALWELL's DARWEN&amp;#8482; AI platform is used to connect WELLTRUST&amp;#8482; patients with life sciences companies, including pharma and biotech trial sponsors and Contract Research Organizations (CROs), by matching trial protocols against the consented patient population. &lt;/li&gt;&lt;li&gt;WELLTRUST&amp;#8482;, a WELL-managed database of consented WELL patients, has surpassed 100,000 patient consents since launching in February 2026. Every consent represents a patient who has expressly agreed to be contacted about clinical trials and research studies matched to their health circumstances. &lt;/li&gt;&lt;li&gt;Patient consents are captured and managed using OceanMD, WELLSTAR's patient engagement platform, which presents the WELLTRUST&amp;#8482; consent within the digital check-in workflow patients already use</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Newsfile/HEALWELL%27s+DARWEN%28TM%29+to+Power+AI-Driven+Clinical+Trial+Matching+for+WELLTRUST%28TM%29%2C+a+Network+of+Over+100%2C000+Consented+Patients/27032822.html</guid>
   <pubDate>Tue, 08 Sep 2026 06:30:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">AIDX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">WELL</category>
   	  </item>
  <item>
   <title>HEALWELL's DARWEN(TM) to Power AI-Driven Clinical Trial Matching for WELLTRUST(TM), a Network of Over 100,000 Consented Patients</title>
   <link>http://www.streetinsider.com/Newsfile/HEALWELL%27s+DARWEN%28TM%29+to+Power+AI-Driven+Clinical+Trial+Matching+for+WELLTRUST%28TM%29%2C+a+Network+of+Over+100%2C000+Consented+Patients/27032822.html</link>
   <description>&lt;ul&gt;&lt;li&gt;HEALWELL's DARWEN&amp;#8482; AI platform is used to connect WELLTRUST&amp;#8482; patients with life sciences companies, including pharma and biotech trial sponsors and Contract Research Organizations (CROs), by matching trial protocols against the consented patient population. &lt;/li&gt;&lt;li&gt;WELLTRUST&amp;#8482;, a WELL-managed database of consented WELL patients, has surpassed 100,000 patient consents since launching in February 2026. Every consent represents a patient who has expressly agreed to be contacted about clinical trials and research studies matched to their health circumstances. &lt;/li&gt;&lt;li&gt;Patient consents are captured and managed using OceanMD, WELLSTAR's patient engagement platform, which presents the WELLTRUST&amp;#8482; consent within the digital check-in workflow patients already use</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Newsfile/HEALWELL%27s+DARWEN%28TM%29+to+Power+AI-Driven+Clinical+Trial+Matching+for+WELLTRUST%28TM%29%2C+a+Network+of+Over+100%2C000+Consented+Patients/27032822.html</guid>
   <pubDate>Tue, 08 Sep 2026 06:30:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">AIDX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">WELL</category>
   	  </item>
  <item>
   <title>HEALWELL to Deploy AI-Powered SMART Search and SMART Summary Across Statewide U.S. Health Information Exchange</title>
   <link>http://www.streetinsider.com/Press+Releases/HEALWELL+to+Deploy+AI-Powered+SMART+Search+and+SMART+Summary+Across+Statewide+U.S.+Health+Information+Exchange/27007944.html</link>
   <description>&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&lt;li&gt;&lt;p&gt;HEALWELL, through its subsidiary Orion Health, has entered into an agreement with the statewide designated Health Information Exchange of Iowa, Converge Health Iowa, to deploy DARWEN&amp;#8482;-powered SMART Search and SMART Summary. &lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;The agreement represents a multi-million-dollar, multi-year enterprise opportunity, and is expected to generate recurring revenue over its term that is substantial relative to the current run rate of HEALWELL's AI &amp;#38; Data Sciences business unit.&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;SMART Search and SMART Summary are designed to reduce clinical burden on physicians at the point of care, extracting relevant clinical facts from complex, longitudinal patient records with document-level traceable provenance. This allows</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/HEALWELL+to+Deploy+AI-Powered+SMART+Search+and+SMART+Summary+Across+Statewide+U.S.+Health+Information+Exchange/27007944.html</guid>
   <pubDate>Tue, 01 Sep 2026 06:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">AIDX</category>
   	  </item>
  <item>
   <title>HEALWELL to Deploy AI-Powered SMART Search and SMART Summary Across Statewide U.S. Health Information Exchange</title>
   <link>http://www.streetinsider.com/Newsfile/HEALWELL+to+Deploy+AI-Powered+SMART+Search+and+SMART+Summary+Across+Statewide+U.S.+Health+Information+Exchange/27007944.html</link>
   <description>&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&lt;li&gt;&lt;p&gt;HEALWELL, through its subsidiary Orion Health, has entered into an agreement with the statewide designated Health Information Exchange of Iowa, Converge Health Iowa, to deploy DARWEN&amp;#8482;-powered SMART Search and SMART Summary. &lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;The agreement represents a multi-million-dollar, multi-year enterprise opportunity, and is expected to generate recurring revenue over its term that is substantial relative to the current run rate of HEALWELL's AI &amp;#38; Data Sciences business unit.&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;SMART Search and SMART Summary are designed to reduce clinical burden on physicians at the point of care, extracting relevant clinical facts from complex, longitudinal patient records with document-level traceable provenance. This allows</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Newsfile/HEALWELL+to+Deploy+AI-Powered+SMART+Search+and+SMART+Summary+Across+Statewide+U.S.+Health+Information+Exchange/27007944.html</guid>
   <pubDate>Tue, 01 Sep 2026 06:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">AIDX</category>
   	  </item>
  <item>
   <title>20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity</title>
   <link>http://www.streetinsider.com/Press+Releases/2020+BioLabs+Reschedules+Investor+Webinar+to+2%3A00+p.m.+Eastern+Time+on+September+2%2C+2026+to+Discuss+OneTest%E2%84%A2+Revenue+and+Expanding+Commercial+Opportunity/26999286.html</link>
   <description>
&lt;p align=&quot;center&quot;&gt;&lt;em&gt;CEO Jonathan Cohen to Detail the Company’s Strongest Quarterly Performance Since Commercial Launch of Multi-Cancer Early Detection Testing, Key Takeaways from the Next Generation Dx Summit, and Path to Broader Commercial Adoption&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;center&quot;&gt;&lt;em&gt;Webinar to Be Held Wednesday, September 2, 2026 at 2:00 p.m. Eastern Time; Registration Is Now Open&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;GAITHERSBURG, Md., Aug.  28, 2026  (GLOBE NEWSWIRE) -- &lt;a target=&quot;_blank&quot; href=&quot;https://www.globenewswire.com/Tracker?data=qvBK8WqQfRKhbwtAdG2-mejAtUjudVkyYn0CyPr-Fdx3a6o8APIS43lw57JzkoQN2Ek4ZPr0rpCurLhfsUqKZyNVNpqBYkmYTLK6SJbG6pM=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;20/20 BioLabs, Inc.&lt;/a&gt; (Nasdaq: AIDX) (“20/20 BioLabs” or the “Company”), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/2020+BioLabs+Reschedules+Investor+Webinar+to+2%3A00+p.m.+Eastern+Time+on+September+2%2C+2026+to+Discuss+OneTest%E2%84%A2+Revenue+and+Expanding+Commercial+Opportunity/26999286.html</guid>
   <pubDate>Fri, 28 Aug 2026 18:26:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">AIDX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.76949781</category>
   	  </item>
  <item>
   <title>20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity</title>
   <link>http://www.streetinsider.com/Press+Releases/2020+BioLabs+Reschedules+Investor+Webinar+to+2%3A00+p.m.+Eastern+Time+on+September+2%2C+2026+to+Discuss+OneTest%E2%84%A2+Revenue+and+Expanding+Commercial+Opportunity/26999286.html</link>
   <description>
&lt;p align=&quot;center&quot;&gt;&lt;em&gt;CEO Jonathan Cohen to Detail the Company’s Strongest Quarterly Performance Since Commercial Launch of Multi-Cancer Early Detection Testing, Key Takeaways from the Next Generation Dx Summit, and Path to Broader Commercial Adoption&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;center&quot;&gt;&lt;em&gt;Webinar to Be Held Wednesday, September 2, 2026 at 2:00 p.m. Eastern Time; Registration Is Now Open&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;GAITHERSBURG, Md., Aug.  28, 2026  (GLOBE NEWSWIRE) -- &lt;a target=&quot;_blank&quot; href=&quot;https://www.globenewswire.com/Tracker?data=qvBK8WqQfRKhbwtAdG2-mejAtUjudVkyYn0CyPr-Fdx3a6o8APIS43lw57JzkoQN2Ek4ZPr0rpCurLhfsUqKZyNVNpqBYkmYTLK6SJbG6pM=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;20/20 BioLabs, Inc.&lt;/a&gt; (Nasdaq: AIDX) (“20/20 BioLabs” or the “Company”), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/2020+BioLabs+Reschedules+Investor+Webinar+to+2%3A00+p.m.+Eastern+Time+on+September+2%2C+2026+to+Discuss+OneTest%E2%84%A2+Revenue+and+Expanding+Commercial+Opportunity/26999286.html</guid>
   <pubDate>Fri, 28 Aug 2026 18:26:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">AIDX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.76949781</category>
   	  </item>
  <item>
   <title>20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity</title>
   <link>http://www.streetinsider.com/Globe+Newswire/2020+BioLabs+Reschedules+Investor+Webinar+to+2%3A00+p.m.+Eastern+Time+on+September+2%2C+2026+to+Discuss+OneTest%E2%84%A2+Revenue+and+Expanding+Commercial+Opportunity/26999286.html</link>
   <description>
&lt;p align=&quot;center&quot;&gt;&lt;em&gt;CEO Jonathan Cohen to Detail the Company’s Strongest Quarterly Performance Since Commercial Launch of Multi-Cancer Early Detection Testing, Key Takeaways from the Next Generation Dx Summit, and Path to Broader Commercial Adoption&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;center&quot;&gt;&lt;em&gt;Webinar to Be Held Wednesday, September 2, 2026 at 2:00 p.m. Eastern Time; Registration Is Now Open&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;GAITHERSBURG, Md., Aug.  28, 2026  (GLOBE NEWSWIRE) -- &lt;a target=&quot;_blank&quot; href=&quot;https://www.globenewswire.com/Tracker?data=qvBK8WqQfRKhbwtAdG2-mejAtUjudVkyYn0CyPr-Fdx3a6o8APIS43lw57JzkoQN2Ek4ZPr0rpCurLhfsUqKZyNVNpqBYkmYTLK6SJbG6pM=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;20/20 BioLabs, Inc.&lt;/a&gt; (Nasdaq: AIDX) (“20/20 BioLabs” or the “Company”), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/2020+BioLabs+Reschedules+Investor+Webinar+to+2%3A00+p.m.+Eastern+Time+on+September+2%2C+2026+to+Discuss+OneTest%E2%84%A2+Revenue+and+Expanding+Commercial+Opportunity/26999286.html</guid>
   <pubDate>Fri, 28 Aug 2026 18:26:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">AIDX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.76949781</category>
   	  </item>
  <item>
   <title>20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity</title>
   <link>http://www.streetinsider.com/Globe+Newswire/2020+BioLabs+Reschedules+Investor+Webinar+to+2%3A00+p.m.+Eastern+Time+on+September+2%2C+2026+to+Discuss+OneTest%E2%84%A2+Revenue+and+Expanding+Commercial+Opportunity/26999286.html</link>
   <description>
&lt;p align=&quot;center&quot;&gt;&lt;em&gt;CEO Jonathan Cohen to Detail the Company’s Strongest Quarterly Performance Since Commercial Launch of Multi-Cancer Early Detection Testing, Key Takeaways from the Next Generation Dx Summit, and Path to Broader Commercial Adoption&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;center&quot;&gt;&lt;em&gt;Webinar to Be Held Wednesday, September 2, 2026 at 2:00 p.m. Eastern Time; Registration Is Now Open&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;GAITHERSBURG, Md., Aug.  28, 2026  (GLOBE NEWSWIRE) -- &lt;a target=&quot;_blank&quot; href=&quot;https://www.globenewswire.com/Tracker?data=qvBK8WqQfRKhbwtAdG2-mejAtUjudVkyYn0CyPr-Fdx3a6o8APIS43lw57JzkoQN2Ek4ZPr0rpCurLhfsUqKZyNVNpqBYkmYTLK6SJbG6pM=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;20/20 BioLabs, Inc.&lt;/a&gt; (Nasdaq: AIDX) (“20/20 BioLabs” or the “Company”), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/2020+BioLabs+Reschedules+Investor+Webinar+to+2%3A00+p.m.+Eastern+Time+on+September+2%2C+2026+to+Discuss+OneTest%E2%84%A2+Revenue+and+Expanding+Commercial+Opportunity/26999286.html</guid>
   <pubDate>Fri, 28 Aug 2026 18:26:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">AIDX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.76949781</category>
   	  </item>
  <item>
   <title>20/20 BioLabs to Host Investor Webinar on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity</title>
   <link>http://www.streetinsider.com/Press+Releases/2020+BioLabs+to+Host+Investor+Webinar+on+September+2%2C+2026+to+Discuss+OneTest%E2%84%A2+Revenue+and+Expanding+Commercial+Opportunity/26977763.html</link>
   <description>&lt;p align=&quot;center&quot;&gt;&lt;em&gt;CEO Jonathan Cohen to Detail the Company’s Strongest Quarterly Performance Since Commercial Launch of Multi-Cancer Early Detection Testing, Key Takeaways from the Next Generation Dx Summit, and Path to Broader Commercial Adoption&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;center&quot;&gt;&lt;em&gt;Webinar to Be Held Wednesday, September 2, 2026 at 12:00 p.m. Eastern Time; Registration Is Now Open&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;GAITHERSBURG, Md., Aug.  26, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=TvUWssidrOesKL9kh-3URyMGhqrj7MloGr4DdvGfIXGxtWWoH70CSSxYblpQ5BQdKSyCu95FErrt6l231-5WaPHn--X3ymvFX1t992YWqnM=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;20/20 BioLabs, Inc.&lt;/a&gt; (Nasdaq: AIDX) (“20/20 BioLabs” or the “Company”), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/2020+BioLabs+to+Host+Investor+Webinar+on+September+2%2C+2026+to+Discuss+OneTest%E2%84%A2+Revenue+and+Expanding+Commercial+Opportunity/26977763.html</guid>
   <pubDate>Wed, 26 Aug 2026 08:31:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">AIDX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">AIDX</category>
   	  </item>
  <item>
   <title>20/20 BioLabs to Host Investor Webinar on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity</title>
   <link>http://www.streetinsider.com/Press+Releases/2020+BioLabs+to+Host+Investor+Webinar+on+September+2%2C+2026+to+Discuss+OneTest%E2%84%A2+Revenue+and+Expanding+Commercial+Opportunity/26977763.html</link>
   <description>&lt;p align=&quot;center&quot;&gt;&lt;em&gt;CEO Jonathan Cohen to Detail the Company’s Strongest Quarterly Performance Since Commercial Launch of Multi-Cancer Early Detection Testing, Key Takeaways from the Next Generation Dx Summit, and Path to Broader Commercial Adoption&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;center&quot;&gt;&lt;em&gt;Webinar to Be Held Wednesday, September 2, 2026 at 12:00 p.m. Eastern Time; Registration Is Now Open&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;GAITHERSBURG, Md., Aug.  26, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=TvUWssidrOesKL9kh-3URyMGhqrj7MloGr4DdvGfIXGxtWWoH70CSSxYblpQ5BQdKSyCu95FErrt6l231-5WaPHn--X3ymvFX1t992YWqnM=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;20/20 BioLabs, Inc.&lt;/a&gt; (Nasdaq: AIDX) (“20/20 BioLabs” or the “Company”), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/2020+BioLabs+to+Host+Investor+Webinar+on+September+2%2C+2026+to+Discuss+OneTest%E2%84%A2+Revenue+and+Expanding+Commercial+Opportunity/26977763.html</guid>
   <pubDate>Wed, 26 Aug 2026 08:31:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">AIDX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">AIDX</category>
   	  </item>
  <item>
   <title>20/20 BioLabs to Host Investor Webinar on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity</title>
   <link>http://www.streetinsider.com/Globe+Newswire/2020+BioLabs+to+Host+Investor+Webinar+on+September+2%2C+2026+to+Discuss+OneTest%E2%84%A2+Revenue+and+Expanding+Commercial+Opportunity/26977763.html</link>
   <description>&lt;p align=&quot;center&quot;&gt;&lt;em&gt;CEO Jonathan Cohen to Detail the Company’s Strongest Quarterly Performance Since Commercial Launch of Multi-Cancer Early Detection Testing, Key Takeaways from the Next Generation Dx Summit, and Path to Broader Commercial Adoption&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;center&quot;&gt;&lt;em&gt;Webinar to Be Held Wednesday, September 2, 2026 at 12:00 p.m. Eastern Time; Registration Is Now Open&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;GAITHERSBURG, Md., Aug.  26, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=TvUWssidrOesKL9kh-3URyMGhqrj7MloGr4DdvGfIXGxtWWoH70CSSxYblpQ5BQdKSyCu95FErrt6l231-5WaPHn--X3ymvFX1t992YWqnM=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;20/20 BioLabs, Inc.&lt;/a&gt; (Nasdaq: AIDX) (“20/20 BioLabs” or the “Company”), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/2020+BioLabs+to+Host+Investor+Webinar+on+September+2%2C+2026+to+Discuss+OneTest%E2%84%A2+Revenue+and+Expanding+Commercial+Opportunity/26977763.html</guid>
   <pubDate>Wed, 26 Aug 2026 08:31:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">AIDX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">AIDX</category>
   	  </item>
  <item>
   <title>20/20 BioLabs to Host Investor Webinar on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity</title>
   <link>http://www.streetinsider.com/Globe+Newswire/2020+BioLabs+to+Host+Investor+Webinar+on+September+2%2C+2026+to+Discuss+OneTest%E2%84%A2+Revenue+and+Expanding+Commercial+Opportunity/26977763.html</link>
   <description>&lt;p align=&quot;center&quot;&gt;&lt;em&gt;CEO Jonathan Cohen to Detail the Company’s Strongest Quarterly Performance Since Commercial Launch of Multi-Cancer Early Detection Testing, Key Takeaways from the Next Generation Dx Summit, and Path to Broader Commercial Adoption&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;center&quot;&gt;&lt;em&gt;Webinar to Be Held Wednesday, September 2, 2026 at 12:00 p.m. Eastern Time; Registration Is Now Open&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;GAITHERSBURG, Md., Aug.  26, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=TvUWssidrOesKL9kh-3URyMGhqrj7MloGr4DdvGfIXGxtWWoH70CSSxYblpQ5BQdKSyCu95FErrt6l231-5WaPHn--X3ymvFX1t992YWqnM=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;20/20 BioLabs, Inc.&lt;/a&gt; (Nasdaq: AIDX) (“20/20 BioLabs” or the “Company”), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/2020+BioLabs+to+Host+Investor+Webinar+on+September+2%2C+2026+to+Discuss+OneTest%E2%84%A2+Revenue+and+Expanding+Commercial+Opportunity/26977763.html</guid>
   <pubDate>Wed, 26 Aug 2026 08:31:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">AIDX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">AIDX</category>
   	  </item>
  <item>
   <title>Form  DEFA14A    20/20 Biolabs, Inc.                  </title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++2020+Biolabs%2C+Inc.++++++++++++++++++/26950845.html</link>
   <description>si-local-file:///var/storage/secattach/20260819/26950845.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++2020+Biolabs%2C+Inc.++++++++++++++++++/26950845.html</guid>
   <pubDate>Wed, 19 Aug 2026 16:51:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">AIDX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.76949781</category>
   	  </item>
  <item>
   <title>Form  DEFA14A    20/20 Biolabs, Inc.                  </title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++2020+Biolabs%2C+Inc.++++++++++++++++++/26950845.html</link>
   <description>si-local-file:///var/storage/secattach/20260819/26950845.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++2020+Biolabs%2C+Inc.++++++++++++++++++/26950845.html</guid>
   <pubDate>Wed, 19 Aug 2026 16:51:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">AIDX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.76949781</category>
   	  </item>
 </channel>
</rss>
